SOLICITATION NOTICE
B -- Services for Generation of Cell Lines from Primary Multiple Myeloma and Monoclonal Gammopathy of Unknown Significance, MGUS Tumors
- Notice Date
- 8/19/2009
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90203-NG1
- Archive Date
- 9/18/2009
- Point of Contact
- Malinda L Holdcraft, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
holdcram@exchange.nih.gov, cr214i@nih.gov
(holdcram@exchange.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), plans to procure on a sole source basis, services for Generation of Cell Lines from Primary Multiple Myeloma and Monoclonal Gammopathy of Unknown Significance, MGUS Tumors with BRT, Inc. 11300 Corobon Lane, Great Falls, Virginia 22066. The North American Industry Classification System Code is 621511 and the business size standard is$12.5M. The requirement is being processed in accordance with the simplified acquisition procedures as stated in FAR 13.106-1 (b)(1). The Multiple Myeloma Research Foundation (MMRF) selected the NCI, as the principal investigator, and the Mayo Clinic, Arizona as the co-investigator, a grant to develop procedures that will enable investigators to establish cell lines from primary multiple myeloma tumors that are not represented by currently available myeloma cell lines. The purpose of this procurement is the development of new ways in which myeloma cell lines can be used to access the value of different therapeutic agents and consequently benefit current research at the NIH/NCI. BRT, Inc. is the only source known to the NCI that can provide the knowledge and experience to develop the procedures required for this study. BRT’s employees have experience in growing primary multiple myeloma tumor cells and multiple myeloma cell lines in tissue culture; experience in isolating and growing normal B- lymphocytes in tissue culture; and using combinations of cytokines that enable the cause of these cells to differentiate into normal plasmablasts and plasma cells. In addition, BRT employees have experience on construction and use of lentiviral agents to efficiently introduce exogenous genes into quiescent or minimally proliferating normal and tumor cells and lentiviral vectors to express several of the genes that are likely needed to generate cell lines from primary myeloma tumor cells. Period of Performance shall be from award through 45 days. This is not a request for competitive quotation. However, if any interested party believes it can perform the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform this requirement. Capability statements must be received in the contracting office by 11am ET, on September 3, 2009. Questions shall be directed to Malinda Holdcraft, Contract Specialist via fax at 301-402-4513 or via electronic mail holdcram@exchange.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certification Applications (ORCA), http://orca.bpn.gov. Please reference number NCI-90203-NG1 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90203-NG1/listing.html)
- Record
- SN01918139-W 20090821/090820000946-b57c27013540e4744758fadf3ce9543f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |